Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sheffield Teaching Hospitals NHS Foundation Trust
With
University of Sheffield
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Women with histological diagnosis of invasive breast cancer requiring neoadjuvant chemotherapy
T2 tumour or above
WHO Performance status of 0,1 or 2
Must consent to or have undergone a core biopsy for diagnosis of breast cancer AND consent to undergo an additional core biopsy prior to the second cycle of chemotherapy (Day 5 +/- Day 21)
Written informed consent
You may not be if
Previous chemotherapy or radiotherapy to treated breast
Evidence of metastatic disease or recurrent breast cancer or previous malignancy (some exceptions)
Calculated creatinine clearance \< 40mls/min
Prior treatment with bisphosphonates in last year or known contraindications to bisphosphonate therapy
Concurrent tamoxifen or aromatase inhibitor medication
Pregnant or lactating women
Cardiac dysfunction that precludes use of anthracycline chemotherapy
Unwilling to have extra interim biopsy
Clareo Health | Investigating the Biological Effects of the Addition of Zoledronic Acid to Pre-operative Chemotherapy in Breast Cancer
